With 1.17 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.86 million shares. The 52-week range on PCRX shows that it touched its highest point at $31.67 and its lowest point at $11.16 during that stretch. It currently has a 1-year price target of $31.71. Beta for the stock currently stands at 0.86.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PCRX was down-trending over the past week, with a drop of -9.07%, but this was down by -12.50% over a month. Three-month performance surged to 36.83% while six-month performance rose 54.09%. The stock lost -23.24% in the past year, while it has gained 21.87% so far this year. A look at the trailing 12-month EPS for PCRX yields -2.20 with Next year EPS estimates of 3.79. For the next quarter, that number is 0.61. This implies an EPS growth rate of -7.15% for this year and 27.39% for next year. EPS is expected to grow by 12.81% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -51.99%.
Float and Shares Shorts:
At present, 46.24 million PCRX shares are outstanding with a float of 44.24 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PCRX since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $3.46578 being high and $3.01157 being low. For PCRX, this leads to a yearly average estimate of $3.14981. Based on analyst estimates, the high estimate for the next quarter is $0.83 and the low estimate is $0.56. The average estimate for the next quarter is thus $0.71.
Summary of Insider Activity:
Insiders traded PCRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
